A compound selected from Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein: X 1 is CR 1 or N; X 2 is CR 2 or N; X 3 is CR 3 or N; R 1, R 2 and R 3 are independently selected from H, F, Cl, CN, -NH 2, -NHCH 3, - N(CH 3) 2, -OH, -OCH 3, -OCH 2 CH 3, -OCH 2 CH 2 OH, and C 1 -C 3 alkyl; X 4, X 5, X 6, and X 7 are independently selected from CH and N; Y 1 and Y 2 are independently selected from CH and N; Z is O or NR, where R is H or C 1 -C 3 alkyl; Q is selected from the groups having the structure: where R 4 is selected from -CH=CH 2, -C(CH 3)=CH 2, -C =CH 2, -C≡CCH 3, and -C≡CH; and R 5 is selected from H and C 1 -C 3 alkyl; R 6a, R 6b, R 7a, and R 7b are independently selected from H, F, Cl, CN, -NH 2, -NHCH 3, -N(CH 3) 2, -OH, -OCH 3, -OCH 2 CH 3, -OCH 2 CH 2 OH, and C 1 -C 3 alkyl; or R 6a and R 7a form a five-, six-, or seven-membered carbocyclyl or heterocyclyl ring; or R 5 and R 6a form a five-, six-, or seven-membered heterocyclyl ring; or if Z is nitrogen, then Z and R 7a, or Z and R 6a form a five-, six-, or seven-membered heterocyclyl ring; R 8 is selected from H, F, Cl, CN, -CH 2 OH, -CH(CH 3)OH, -C(CH 3) 2 OH,-CH(CF 3)OH, -CH 2 F, -CHF 2, -CH 2 CHF 2, -CF 3, -C NH 2, -C NHCH 3, -C N(CH 3) 2, -NH 2, -NHCH 3, -N(CH 3) 2, -NHC CH 3, -OH, -OCH 3, -OCH 2 CH 3, -OCH 2 CH 2 OH, cyclopropyl, cyclopropylmethyl, 1-hydroxycyclopropyl, imidazolyl, pyrazolyl, 3-hydroxy-oxetan-3-yl, oxetan-3-yl, and azetidin-1-yl; R 9 is selected from the structures: where the wavy line indicates the site of attachment; and where alkyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with one or more groups independently selected from F, Cl, Br, I, -CN, -CH 3, -CH 2 CH 3,-CH(CH 3) 2, -CH 2 CH(CH 3) 2, -CH 2 OH, -CH 2 OCH 3, -CH 2 CH 2 OH, -C(CH 3) 2 OH,-CH CH(CH 3) 2, -C(CH 3) 2 CH 2 OH, -CH 2 CH 2 SO 2 CH 3, -CH 2 OP 2, -CH 2 F,-CHF 2, -CF 3, -CH 2 CF 3, -CH 2 CHF 2, -CH(CH 3)CN, -C(CH 3) 2 CN, -CH 2 CN, -CO 2 H,-COCH 3, -CO 2 CH 3, -CO 2 C(CH 3) 3, -COCH CH 3, -CONH 2, -CONHCH 3, -CON(CH 3) 2, -C(CH 3) 2 CONH 2, -NH 2, -NHCH 3, -N(CH 3) 2, -NHCOCH 3, -N(CH 3)COCH 3,-NHS 2 CH 3, -N(CH 3)C(CH 3) 2 CONH 2, -N(CH 3)CH 2 CH 2 S 2 CH 3, -NO 2, =O, -OH,-OCH 3, -OCH 2 CH 3, -OCH 2 CH 2 OCH 3, -OCH 2 CH 2 OH, -OCH 2 CH 2 N(CH 3) 2, -OP 2, -S 2 N(CH 3) 2, -SCH 3, -S 2 CH 3, -S 3 H, cyclopropyl, oxetanyl, azetidinyl, 1-methylazetidin-3-yl)oxy, N-methyl-N-oxetan-3-ylamino, azetidin-1-ylmethyl, pyrrolidin-1-yl, and morpholino. X 1 is CR 1 or N; X 2 is CR 2 or N; X 3 is CR 3 or N; R 1, R 2 and R 3 are independently selected from H, F, Cl, CN, -NH 2, -NHCH 3, - N(CH 3) 2, -OH, -OCH 3, -OCH 2 CH 3, -OCH 2 CH 2 OH, and C 1 -C 3 alkyl; X 4, X 5, X 6, and X 7 are independently selected from CH and N; Y 1 and Y 2 are independently selected from CH and N; Z is O or NR, where R is H or C 1 -C 3 alkyl; Q is selected from the groups having the structure: where R 4 is selected from -CH=CH 2, -C(CH 3)=CH 2, -C =CH 2, -C≡CCH 3, and -C≡CH; and R 5 is selected from H and C 1 -C 3 alkyl; R 6a, R 6b, R 7a, and R 7b are independently selected from H, F, Cl, CN, -NH 2, -NHCH 3, -N(CH 3) 2, -OH, -OCH 3, -OCH 2 CH 3, -OCH 2 CH 2 OH, and C 1 -C 3 alkyl; or R 6a and R 7a form a five-, six-, or seven-membered carbocyclyl or heterocyclyl ring; or R 5 and R 6a form a five-, six-, or seven-membered heterocyclyl ring; or if Z is nitrogen, then Z and R 7a, or Z and R 6a form a five-, six-, or seven-membered heterocyclyl ring; R 8 is selected from H, F, Cl, CN, -CH 2 OH, -CH(CH 3)OH, -C(CH 3) 2 OH,-CH(CF 3)OH, -CH 2 F, -CHF 2, -CH 2 CHF 2, -CF 3, -C NH 2, -C NHCH 3, -C N(CH 3) 2, -NH 2, -NHCH 3, -N(CH 3) 2, -NHC CH 3, -OH, -OCH 3, -OCH 2 CH 3, -OCH 2 CH 2 OH, cyclopropyl, cyclopropylmethyl, 1-hydroxycyclopropyl, imidazolyl, pyrazolyl, 3-hydroxy-oxetan-3-yl, oxetan-3-yl, and azetidin-1-yl; R 9 is selected from the structures: where the wavy line indicates the site of attachment; and where alkyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with one or more groups independently selected from F, Cl, Br, I, -CN, -CH 3, -CH 2 CH 3,-CH(CH 3) 2, -CH 2 CH(CH 3) 2, -CH 2 OH, -CH 2 OCH 3, -CH 2 CH 2 OH, -C(CH 3) 2 OH,-CH CH(CH 3) 2, -C(CH 3) 2 CH 2 OH, -CH 2 CH 2 SO 2 CH 3, -CH 2 OP 2, -CH 2 F,-CHF 2, -CF 3, -CH 2 CF 3, -CH 2 CHF 2, -CH(CH 3)CN, -C(CH 3) 2 CN, -CH 2 CN, -CO 2 H,-COCH 3, -CO 2 CH 3, -CO 2 C(CH 3) 3, -COCH CH 3, -CONH 2, -CONHCH 3, -CON(CH 3) 2, -C(CH 3) 2 CONH 2, -NH 2, -NHCH 3, -N(CH 3) 2, -NHCOCH 3, -N(CH 3)COCH 3,-NHS 2 CH 3, -N(CH 3)C(CH 3) 2 CONH 2, -N(CH 3)CH 2 CH 2 S 2 CH 3, -NO 2, =O, -OH,-OCH 3, -OCH 2 CH 3, -OCH 2 CH 2 OCH 3, -OCH 2 CH 2 OH, -OCH 2 CH 2 N(CH 3) 2, -OP 2, -S 2 N(CH 3) 2, -SCH 3, -S 2 CH 3, -S 3 H, cyclopropyl, oxetanyl, azetidinyl, 1-methylazetidin-3-yl)oxy, N-methyl-N-oxetan-3-ylamino, azetidin-1-ylmethyl, pyrrolidin-1-yl, and morpholino.